This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Randomized Controlled Trial  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic  Social Bookmarking   What's this?

A Randomized Controlled Trial

Publication Committee for the VMAC Investigators

JAMA. 2002;287:1531-1540.

Context  Decompensated congestive heart failure (CHF) is the leading hospital discharge diagnosis in patients older than 65 years.

Objective  To compare the efficacy and safety of intravenous nesiritide, intravenous nitroglycerin, and placebo.

Design, Setting, and Patients  Randomized, double-blind trial of 489 inpatients with dyspnea at rest from decompensated CHF, including 246 who received pulmonary artery catheterization, that was conducted at 55 community and academic hospitals between October 1999 and July 2000.

Interventions  Intravenous nesiritide (n = 204), intravenous nitroglycerin (n = 143), or placebo (n = 142) added to standard medications for 3 hours, followed by nesiritide (n = 278) or nitroglycerin (n = 216) added to standard medication for 24 hours.

Main Outcome Measures  Change in pulmonary capillary wedge pressure (PCWP) among catheterized patients and patient self-evaluation of dyspnea at 3 hours after initiation of study drug among all patients. Secondary outcomes included comparisons of hemodynamic and clinical effects between nesiritide and nitroglycerin at 24 hours.

Results  At 3 hours, the mean (SD) decrease in PCWP from baseline was –5.8 (6.5) mm Hg for nesiritide (vs placebo, P<.001; vs nitroglycerin, P = .03), –3.8 (5.3) mm Hg for nitroglycerin (vs placebo, P = .09), and –2 (4.2) mm Hg for placebo. At 3 hours, nesiritide resulted in improvement in dyspnea compared with placebo (P = .03), but there was no significant difference in dyspnea or global clinical status with nesiritide compared with nitroglycerin. At 24 hours, the reduction in PCWP was greater in the nesiritide group (-8.2 mm Hg) than the nitroglycerin group (-6.3 mm Hg), but patients reported no significant differences in dyspnea and only modest improvement in global clinical status.

Conclusion  When added to standard care in patients hospitalized with acutely decompensated CHF, nesiritide improves hemodynamic function and some self-reported symptoms more effectively than intravenous nitroglycerin or placebo.

VMAC Committees, Investigators, and Centers: Publication Committee: James B. Young, Cleveland Clinic Foundation; William T. Abraham, University of Kentucky, Lexington; Lynne Warner Stevenson, Brigham and Women's Hospital; Darlene P. Horton, Scios Inc; Uri Elkayam, Los Angeles County-USC Medical Center; Robert C. Bourge, University of Alabama, Birmingham. Steering Committee: James B. Young (chairperson), Cleveland Clinic Foundation; William T. Abraham, University of Kentucky, Lexington; Lynne Warner Stevenson, Brigham and Women's Hospital; Charles L. Emerman, MetroHealth Medical Center; Darlene P. Horton (sponsor representative). Statistical Analysis: Mei L. Cheng, Scios Inc. Nesiritide Pharmacokinetic/Pharmacodynamic Modeling: Nancy Sambol, University of California, San Francisco. Investigators and Centers (in alphabetical order by center): Albert Einstein Hospital (Thierry LeJemtel); Baylor College of Medicine (Guillermo Torre); Beth Israel Deaconess Medical Center (Andrew Burger); Buxmont Cardiology Associates, Lifemark Medical Center (Mitchell Greenspan); Cardiac Centers of LA at Willis Knighton Heart Institute (Jalal Ghali); Cardiology Associates of Gainesville (Steven F. Roark); Cardiovascular Medicine of Virginia at Pratt Medical Center Ltd (Robert Vranian); Cardiovascular Research Institute of Dallas (Martin Berk); Cardiovascular Research Institute of Southern California (Ronald Karlsberg); Care Group (Mary N. Walsh); Christ Hospital and Medical Center (Marc A. Silver); Community Hospital East (Edward Harlamert); Dartmouth Hitchcock Medical Center (Bruce D. Hettleman); Dorn Research Institute (Constantine Hassapoyannes); Durham VA Medical Center (Frederick R. Cobb); George Washington University Medical Center (Jacob Varghese); HeartCare Midwest (Alan Chu); Heart Center, Huntsville Hospital (W. Herbert Haught); Heart Institute of St Petersburg (Michael E. McIvor, Gregg Schuyler); Hennepin County Medical Center (Steven R. Goldsmith); Hillsboro Cardiology (Steven Promisloff); Jacksonville Center for Clinical Research (Michael Koren); Jacksonville Heart Center (Jay Dinerman); Johns Hopkins Hospital (Joshua Hare); Los Angeles County-USC Medical Center (Uri Elkayam); Med-Tech Research Inc (Salah El Hafi); Medical Research Consortium at Winona Memorial Hospital (Jack Hall); MediQuest Research Group Inc (Robert Feldman); Montefiore Medical Center (Robert Moskowitz); Mount Sinai Medical Center (Marrick Kukin, Gervasio Lamas); Northwestern Memorial Hospital (William Cotts); Oregon Health Sciences University (Ray Hershberger); Roudebush VA Medical Center (Lincoln E. Ford); Rush-Presbyterian-St Luke's Medical Center (Walter Kao); St Paul Heart Clinic (Alan J. Bank); San Diego Cardiac Center (Peter M. Hoagland); San Diego Cardiovascular Research Associates (George Dennish); Scripps Clinic, Heart, Lung, Vascular Center (Allen D. Johnson); Stern Cardiovascular Center (Frank A. McGrew); University of Alabama at Birmingham (Mark F. Aaron, Robert C. Bourge); University of Arizona Health Sciences Center (Charles Y. Lui); University of California, San Francisco Medical Center (Teresa DeMarco); James A. Haley Veterans Hospital, Tampa, Fla (Doug Schocken); University of Cincinnati Medical Center (Lynne Wagoner); University of Florida Medical Center, Jacksonville (Alan B. Miller); University of Florida Health Sciences Center, Gainesville (James A. Hill); University of Iowa Hospitals and Clinics (Ron M. Oren); University of Kansas Medical Center (David Wilson); University of Louisville Research Foundation (Geetha Bhat); University of Maryland Medical System (Stephen S. Gottlieb); University of Miami/Jackson Memorial Medical Center (Stephen M. Mallon); University of Missouri Health Sciences Center (Hanumanth Reddy); University of Rochester Medical Center (Chang-seng Liang); University of South Dakota School of Medicine (Kevin Vaska); University of Washington Medical Center (Daniel Fishbein); Vanderbilt University Medical Center (John R. Wilson); VA Medical Center IIIB (A. Maziar Zafari); Watson Clinic (Kevin Browne).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Nesiritide vs Nitroglycerin for Decompensated Congestive Heart Failure
Scott Dunavant, William Rifkin, and James B. Young
JAMA. 2002;288(5):571-573.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure: A Randomized Controlled Trial
Michael S. Cuffe, Robert M. Califf, Kirkwood F. Adams, Jr, Raymond Benza, Robert Bourge, Wilson S. Colucci, Barry M. Massie, Christopher M. O'Connor, Ileana Pina, Rebecca Quigg, Marc A. Silver, Mihai Gheorghiade, and for the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure Investigators
JAMA. 2002;287(12):1541-1547.
ABSTRACT | FULL TEXT  

Treatment of Acute Heart Failure: Out With the Old, In With the New
Philip A. Poole-Wilson
JAMA. 2002;287(12):1578-1580.
EXTRACT | FULL TEXT  

March 27, 2002
JAMA. 2002;287(12):1587-1588.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacists' role in facilitating evidence-based prescribing for unlabeled use of medications
Macaulay et al.
Am J Health Syst Pharm 2009;66:1735-1739.
FULL TEXT  

Effects of tolvaptan on dyspnoea relief from the EVEREST trials
Pang et al.
Eur Heart J 2009;30:2233-2240.
ABSTRACT | FULL TEXT  

Therapeutic potential of infused cardiac natriuretic peptides in myocardial infarction
Richards
Heart 2009;95:1299-1300.
FULL TEXT  

Intravenous therapy for hypertensive emergencies, part 1
Rhoney and Peacock
Am J Health Syst Pharm 2009;66:1343-1352.
ABSTRACT | FULL TEXT  

Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury
George et al.
Am. J. Physiol. Heart Circ. Physiol. 2009;297:H708-H717.
ABSTRACT | FULL TEXT  

Palliative care in congestive heart failure.
Goodlin
J Am Coll Cardiol 2009;54:386-396.
ABSTRACT | FULL TEXT  

Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide
Pan et al.
Proc. Natl. Acad. Sci. USA 2009;106:11282-11287.
ABSTRACT | FULL TEXT  

Are BNP Changes During Hospitalization for Heart Failure a Reliable Surrogate for Predicting the Effects of Therapies on Post-Discharge Mortality?
Gheorghiade and Pang
J Am Coll Cardiol 2009;53:2349-2352.
FULL TEXT  

End points for clinical trials in acute heart failure syndromes.
Allen et al.
J Am Coll Cardiol 2009;53:2248-2258.
ABSTRACT | FULL TEXT  

Cinaciguat (BAY 58-2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure
Lapp et al.
Circulation 2009;119:2781-2788.
ABSTRACT | FULL TEXT  

Soluble Guanylate Cyclase: Not a Dull Enzyme
Boerrigter and Burnett
Circulation 2009;119:2752-2754.
FULL TEXT  

Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD-NP, in a First-in-Human Clinical Trial in Healthy Subjects
Lee et al.
J Clin Pharmacol 2009;49:668-673.
ABSTRACT | FULL TEXT  

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
Hunt et al.
J Am Coll Cardiol 2009;53:e1-e90.
FULL TEXT  

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
Jessup et al.
J Am Coll Cardiol 2009;53:1343-1382.
FULL TEXT  

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
2009 WRITING GROUP TO REVIEW NEW EVIDENCE AND UPDA et al.
Circulation 2009;119:1977-2016.
FULL TEXT  

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
2005 WRITING COMMITTEE MEMBERS et al.
Circulation 2009;119:e391-e479.
FULL TEXT  

Acute heart failure syndromes.
Gheorghiade and Pang
J Am Coll Cardiol 2009;53:557-573.
ABSTRACT | FULL TEXT  

Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment.
Flaherty et al.
J Am Coll Cardiol 2009;53:254-263.
ABSTRACT | FULL TEXT  

Heart Failure and Cardiac Pulmonary Edema
Hollenberg
ACCP Crit Care Med Brd Rev 2009;20:117-128.
FULL TEXT  

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction: An International, Multicenter, Randomized, Placebo-Controlled Trial
Udelson et al.
J Am Coll Cardiol 2008;52:1540-1545.
ABSTRACT | FULL TEXT  

Assessment of renal hemodynamic effects of nesiritide in patients with heart failure using intravascular Doppler and quantitative angiography.
Elkayam et al.
J Am Coll Cardiol Img 2008;1:765-771.
ABSTRACT | FULL TEXT  

Hemodynamic Effects and Safety of Nesiritide in Neonates with Heart Failure
Simsic et al.
J Intensive Care Med 2008;23:389-395.
ABSTRACT  

Effects of Continuous Aortic Flow Augmentation in Patients With Exacerbation of Heart Failure Inadequately Responsive to Medical Therapy: Results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM)
Greenberg et al.
Circulation 2008;118:1241-1249.
ABSTRACT | FULL TEXT  

Preliminary Experience With Nesiritide in Pediatric Patients Less Than 12 Months of Age
Ryan et al.
J Intensive Care Med 2008;23:321-328.
ABSTRACT  

Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452
Coletta et al.
Eur J Heart Fail 2008;10:917-920.
ABSTRACT | FULL TEXT  

Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia
Finley et al.
Circulation 2008;118:410-421.
FULL TEXT  

Vasodilator therapy for decompensated heart failure.
Yancy
J Am Coll Cardiol 2008;52:208-210.
FULL TEXT  

Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide: CD-NP.
Lisy et al.
J Am Coll Cardiol 2008;52:60-68.
ABSTRACT | FULL TEXT  

Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction
Kasama et al.
Eur Heart J 2008;29:1485-1494.
ABSTRACT | FULL TEXT  

The Tumultuous Journey of Nesiritide: Past, Present, and Future
Burnett and Korinek
Circ Heart Fail 2008;1:6-8.
FULL TEXT  

Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure: Results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial
Yancy et al.
Circ Heart Fail 2008;1:9-16.
ABSTRACT | FULL TEXT  

B-type natriuretic peptide infusions in acute myocardial infarction
Hillock et al.
Heart 2008;94:617-622.
ABSTRACT | FULL TEXT  

Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis
Peacock et al.
Emerg. Med. J. 2008;25:205-209.
ABSTRACT | FULL TEXT  

A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach
Pang et al.
Eur Heart J 2008;29:816-824.
ABSTRACT | FULL TEXT  

Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective
Kazory and Ross
Circulation 2008;117:975-983.
ABSTRACT | FULL TEXT  

Overview of emerging pharmacologic agents for acute heart failure syndromes
De Luca et al.
Eur J Heart Fail 2008;10:201-213.
ABSTRACT | FULL TEXT  

Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure: The VERITAS Randomized Controlled Trials
McMurray et al.
JAMA 2007;298:2009-2019.
ABSTRACT | FULL TEXT  

Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Witteles et al.
J Am Coll Cardiol 2007;50:1835-1840.
ABSTRACT | FULL TEXT  

Effect of nesiritide on renal function in patients admitted for decompensated heart failure
Arora et al.
QJM 2007;100:699-706.
ABSTRACT | FULL TEXT  

Biomarkers in Heart Failure: Does Prognostic Utility Translate to Clinical Futility?
Maisel
J Am Coll Cardiol 2007;50:1061-1063.
FULL TEXT  

Intermittent Outpatient Nesiritide Infusion Reduces Hospital Admissions in Patients With Advanced Heart Failure
Schwarz et al.
J CARDIOVASC PHARMACOL THER 2007;12:232-236.
ABSTRACT  

Nesiritide and renal function after cardiac surgery
Dunn and Sachak
Am J Health Syst Pharm 2007;64:1582-1584.
FULL TEXT  

Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: The SURVIVE Randomized Trial
Mebazaa et al.
JAMA 2007;297:1883-1891.
ABSTRACT | FULL TEXT  

Immunoreactivity and Guanosine 3',5'-Cyclic Monophosphate Activating Actions of Various Molecular Forms of Human B-Type Natriuretic Peptide
Heublein et al.
Hypertension 2007;49:1114-1119.
ABSTRACT | FULL TEXT  

Effect of Nesiritide Infusion Duration on Renal Function in Acutely Decompensated Heart Failure Patients
Chow et al.
The Annals of Pharmacotherapy 2007;41:556-561.
ABSTRACT | FULL TEXT  

Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure: The EVEREST Outcome Trial
Konstam et al.
JAMA 2007;297:1319-1331.
ABSTRACT | FULL TEXT  

Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure: The EVEREST Clinical Status Trials
Gheorghiade et al.
JAMA 2007;297:1332-1343.
ABSTRACT | FULL TEXT  

Alternate Circulating Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide Forms in the General Population
Lam et al.
J Am Coll Cardiol 2007;49:1193-1202.
ABSTRACT | FULL TEXT  

Management of acute decompensated heart failure
Allen and O'Connor
CMAJ 2007;176:797-805.
ABSTRACT | FULL TEXT  

Acute Phosphodiesterase 5 Inhibition Mimics Hemodynamic Effects of B-Type Natriuretic Peptide and Potentiates B-Type Natriuretic Peptide Effects in Failing But Not Normal Canine Heart
Forfia et al.
J Am Coll Cardiol 2007;49:1079-1088.
ABSTRACT | FULL TEXT  

Nesiritide Administration in Patients With Left Ventricular Dysfunction Undergoing Coronary Artery Bypass Surgery
Belenkie
J Am Coll Cardiol 2007;49:727-728.
FULL TEXT  

Effects of Perioperative Nesiritide in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery: The NAPA Trial
Mentzer et al.
J Am Coll Cardiol 2007;49:716-726.
ABSTRACT | FULL TEXT  

Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside
deGoma et al.
J Am Coll Cardiol 2006;48:2397-2409.
ABSTRACT | FULL TEXT  

Risk of worsening renal function with nesiritide following cardiac surgery
Kristeller et al.
Am J Health Syst Pharm 2006;63:2351-2353.
ABSTRACT | FULL TEXT  

Haemodynamic and clinical effects of ularitide in decompensated heart failure
Mitrovic et al.
Eur Heart J 2006;27:2823-2832.
ABSTRACT | FULL TEXT  

Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.
Gheorghiade et al.
JAMA 2006;296:2217-2226.
ABSTRACT | FULL TEXT  

Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure
Chen et al.
Eur J Heart Fail 2006;8:681-686.
ABSTRACT | FULL TEXT  

Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study
Zannad et al.
Eur J Heart Fail 2006;8:697-705.
ABSTRACT | FULL TEXT  

Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.
Hauptman et al.
JAMA 2006;296:1877-1884.
ABSTRACT | FULL TEXT  

Risk of death associated with nesiritide in patients with acutely decompensated heart failure.
Aaronson and Sackner-Bernstein
JAMA 2006;296:1465-1466.
FULL TEXT  

Nesiritide: trials and tribulations.
Arora
J CARDIOVASC PHARMACOL THER 2006;11:165-169.
ABSTRACT  

Perioperative management of chronic heart failure.
Groban and Butterworth
Anesth. Analg. 2006;103:557-575.
ABSTRACT | FULL TEXT  

Clinical application of the natriuretic peptides in heart failure
Chen and Burnett
Eur Heart J Suppl 2006;8:E18-E25.
ABSTRACT | FULL TEXT  

Bronchodilator effect of infused B-type natriuretic Peptide in asthma.
Akerman et al.
Chest 2006;130:66-72.
ABSTRACT | FULL TEXT  

The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
Kesselheim et al.
Health Aff (Millwood) 2006;25:1095-1102.
ABSTRACT | FULL TEXT  

Relevance of Brain Natriuretic Peptide in Preload-Dependent Regulation of Cardiac Sarcoplasmic Reticulum Ca2+ ATPase Expression
Kogler et al.
Circulation 2006;113:2724-2732.
ABSTRACT | FULL TEXT  

Nonhypotensive Low-Dose Nesiritide Has Differential Renal Effects Compared With Standard-Dose Nesiritide in Patients With Acute Decompensated Heart Failure and Renal Dysfunction
Riter et al.
J Am Coll Cardiol 2006;47:2334-2335.
FULL TEXT  

Nesiritide: The Latest Drug for Treating Heart Failure
Fontana
Crit Care Nurse 2006;26:39-47.
FULL TEXT  

The role of natriuretic peptides in cardioprotection
Nishikimi et al.
Cardiovasc Res 2006;69:318-328.
ABSTRACT | FULL TEXT  

Clinical Presentation, Management, and In-Hospital Outcomes of Patients Admitted With Acute Decompensated Heart Failure With Preserved Systolic Function: A Report From the Acute Decompensated Heart Failure National Registry (ADHERE) Database
Yancy et al.
J Am Coll Cardiol 2006;47:76-84.
ABSTRACT | FULL TEXT  

Perioperative Effects and Safety of Nesiritide Following Cardiac Surgery in Children
Simsic et al.
J Intensive Care Med 2006;21:22-26.
ABSTRACT  

Acute Heart Failure Syndromes: Current State and Framework for Future Research
Gheorghiade et al.
Circulation 2005;112:3958-3968.
FULL TEXT  

Nesiritide for outpatient treatment of heart failure
Bauer and Randazzo
Am J Health Syst Pharm 2005;62:2639-2642.
FULL TEXT  

Early Ultrafiltration in Patients With Decompensated Heart Failure and Diuretic Resistance
Costanzo et al.
J Am Coll Cardiol 2005;46:2047-2051.
ABSTRACT | FULL TEXT  

Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons
Aronow
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2005;60:1597-1605.
ABSTRACT | FULL TEXT  

Vasopressin Antagonism in Heart Failure
Goldsmith and Gheorghiade
J Am Coll Cardiol 2005;46:1785-1791.
ABSTRACT | FULL TEXT  

Nesiritide--not verified.
Sackner-Bernstein et al.
NEJM 2005;353:1525-1527.
FULL TEXT  

Reliability of Nesiritide Infusion via Non-Primed Tubing and Heparin-Coated Catheters
Onat et al.
The Annals of Pharmacotherapy 2005;39:1617-1619.
ABSTRACT | FULL TEXT  

Effect of cardiopulmonary bypass and surgical intervention on the natriuretic hormone system in children
Costello et al.
J. Thorac. Cardiovasc. Surg. 2005;130:822-829.
ABSTRACT | FULL TEXT  

Risk of Death With Nesiritide--Reply
Sackner-Bernstein and Aaronson
JAMA 2005;294:898-898.
FULL TEXT